Amneal Acquires Kashiv BioSciences for $300B Biosimilar Market Play — Amneal Pharmaceuticals, Inc.

Event summary

Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences on August 10, 2026.
The deal creates a fully integrated global biosimilars platform with end-to-end capabilities in R&D, manufacturing, and commercialization.
$300 billion in projected global biologics loss-of-exclusivity over the next decade is targeted for capture.
Kashiv’s U.S. and India-based operations bring robust infrastructure and skilled teams to Amneal’s portfolio.

The big picture

The acquisition positions Amneal to dominate the biosimilars market, leveraging Kashiv’s U.S. and India-based operations to capture a significant share of the $300 billion biologics loss-of-exclusivity wave. This move aligns with broader industry trends toward consolidation and vertical integration in biopharmaceuticals, aiming to streamline production and reduce costs.

What we're watching

Integration Execution: How Amneal will merge Kashiv’s R&D and manufacturing capabilities with its commercial scale.
Market Timing: The pace at which the combined entity can launch multiple biosimilars annually to capitalize on biologics loss of exclusivity.
Competitive Positioning: Whether Amneal can solidify its claim as America’s #1 Affordable Medicines company amid intense industry competition.